May 20th

Neose Receives Milestone Payment from Novo Nordisk on Factor IX Program

Neose Technologies, Inc. (NasdaqGM:NTEC) today announced that it received a milestone payment from Novo Nordisk A/S (NYSE:NVO) under a license agreement for the use of Neose\'s GlycoPEGylation(TM) technology to develop a next-generation version of Factor IX. The Company is also working with Novo Nordisk under separate license agreements to develop GlycoPEGylated versions of recombinant Factors VIIa and VIII. A Phase I trial of GlycoPEG-Factor VIIa is currently ongoing.

\"We are excited about Novo Nordisk\'s continued progress in developing a long-acting Factor IX using our GlycoPEGylation technology,\" said George J. Vergis, Ph.D., Neose president and chief executive officer. About Coagulation Factor IX

Factor IX products are used in the treatment of Hemophilia B. Hemophilia B is caused by a deficiency of a blood plasma protein called factor IX that affects the clotting property of blood. According to the National Hemophilia Foundation, Hemophilia B is the second most common type of hemophilia, occurring in about one in 25,000 male births. In the United States, Hemophilia B affects about 3,300 individuals. The worldwide market for recombinant Factor IX was approximately $360 million in 2006.

About Novo Nordisk A/S

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk\'s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol \'NVO\'. For more information, visit www.novonordisk.com.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market. The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Factor VIII, and Factor IX, target markets with aggregate 2006 sales of approximately $8 billion. For more information, please visit www.neose.com.

For more information, please visit www.neose.com.

Neose \"Safe Harbor\" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are \"forward-looking statements\" that involve risks and uncertainties, including without limitation the risk that the collaboration will not continue or will not be successful, or that a next-generation version of Factor IX will not be successfully developed. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the sections of Neose\'s Annual Report on Form 10-K for the year ended December 31, 2007, entitled \"Risk Factors\" and \"Special Note Regarding Forward-Looking Statements\" and discussions of potential risks and uncertainties in Neose\'s subsequent filings with the SEC.

SOURCE: Neose Technologies, Inc.

Neose Technologies, Inc. A. Brian Davis Sr. Vice President and Chief Financial Officer (215) 315-9000